Article Figures & Data
Tables
- Table 1. A GP’s perception of patient request for antibiotics by country, age, infection subgroup, and comorbidity
Yes (%)
n = 611a (12)No (%)
n = 4356a (88)P valueb Country <0.0001 Armenia 34 (10) 321 (90) Belgium 16 (6) 272 (94) Croatia 11 (4) 259 (96) Denmark 23 (6) 366 (94) France 39 (15) 223 (85) Georgia 26 (11) 214 (89) Germany 5 (2) 235 (98) Greece 115 (49)* 118 (51) Hungary 28 (9) 273 (91) Ireland 79 (27)* 211 (73) Moldova 26 (11) 214 (89) Norway 16 (8) 195 (92) Poland 31 (13) 210 (87) Romania 20 (8) 227 (92) Spain 12 (4) 279 (96) The Netherlands 28 (9) 289 (91) Ukraine 59 (24)* 185 (76) UK 43 (14) 265 (86) Age <0.001 0–19 147 (8) 1598 (92) 20–49 221 (13) 1541 (87) 50–100 241 (17) 1211 (83) Comorbidities <0.0001 No 373 (11) 3159 (89) Yes 234 (17) 1183 (83) Fever <0.0001 No 193 (9) 1951 (91) Yes 417 (15) 2399 (85) Coughc 0.21 No 97 (11) 771 (89) Yes 514 (13) 3575 (87) Sore throatc 0.003 No 215 (10) 1852 (90) Yes 394 (14) 2488 (86) Countries with the highest proportion of perceived antibiotic requests are highlighted in bold, with asterisk.aIf numbers do not add up to the column total, this is owing to missing data. bχ2 testing was used to compare variable proportions between patients for whom an antibiotic request was perceived and not. Two-sided testing at a 5% significance level were used. cCough and sore throat indicate a reported symptom, not a diagnosis
- Table 2. Multivariable analysis of determinants of antibiotic prescribing, taking into account a GP’s perception of a patient request for antibiotics (overall), and clinical examination findings for the subgroups diagnosed with a lower respiratory tract infection (LRTI), throat infection, and influenza-like-illness (ILI)
All
(n = 4746)LRTI
(n = 1519)Throat infection
(n = 1632)ILI (n = 1046) Adj ORa 95% CI Adj ORa 95% CI Adj ORa 95% CI Adj ORa 95% CI Use of POC test(s) 1.34 0.97 to 1.86 0.66 0.38 to 1.15 0.92 0.46 to 1.87 1.61 0.50 to 5.21 Illness severity: moderate 7.47* 6.22 to 8.96 5.38* 3.84 to 7.52 6.39* 4.35 to 9.31 4.65* 2.17 to 9.95 Illness severity: severe 9.94* 6.60 to 4.97 3.61* 1.99 to 6.53 1.46 0.39 to 5.45 3.27 0.46 to 23.28 Age (year) 1.01* 1.01 to 1.02 1.02* 1.01 to 1.03 1.01 1.00 to 1.02 0.99 0.97 to 1.01 Comorbidity 1.27* 1.04 to 1.55 1.05 0.75 to 1.48 1.08 0.67 to 1.72 1.37 0.60 to 3.13 Fever 1.50* 1.25 to 1.80 2.46* 1.77 to 3.42 1.18 0.67 to 1.73 1.59 0.69 to 3.66 Duration (day) 1.03* 1.01 to 1.04 1.02 1.00 to 1.05 1.06* 1.01 to 1.12 1.04 0.98 to 1.10 Request for antibiotics 4.35* 3.41 to 5.54 2.87* 1.92 to 4.31 5.05* 3.05 to 8.36 13.86* 5.47 to 35.11 Dyspnoea 1.35 0.96 to 1.90 Chest pain 1.11 0.66 to 1.89 Abnormal lung auscultation 3.09* 2.27 to 4.21 3.76* 1.51 to 9.37 Sputum 2.34* 1.73 to 3.16 2.65* 1.19 to 5.93 Wheeze 0.58* 0.41 to 0.82 Tachypnoea 0.99 0.59 to 1.67 Tonsillar exudate 16.43* 10.65 to 25.33 Swollen tonsils 2.64* 1.84 to 3.80 Tender cervical nodes 1.46 0.99 to 2.17 Peritonsillar abscess 4.35 0.41 to 46.19 Country Appendix, Supplementary Table S2 Multivariable mixed effects logistic regression for the dependent variable antibiotic prescribing controlling for age, comorbidity, fever, perceived illness severity, illness duration, perceived request for antibiotics, country and strep A and/or C-reactive protein (CRP) point-of-care (POC) testing for all patients. Three important subgroups, patients diagnosed with a LRTI, throat infection, or ILI were further studied; relevant clinical examination findings, with a significant association in univariable analysis, were included. CRP testing was included for patients with a LRTI and strep A for patients with a throat infection. Practice was included as random effect. No interaction terms were added to the models. Reference categories were ‘no’ for POC testing, comorbidity, fever,, and perceived request, ‘mild’ for illness severity, and Belgium (lowest antibiotic prescribing proportion) for country. For age and duration of symptoms an increase of one unit was considered. aAdjusted odds ratios (OR) and 95% confidence intervals (CI); values significant at the 5% significance level in bold.
Supplementary Data
- Dom_10.3399BJGPO.2024.0166_supp.docx -
Supplementary material is not copyedited or typeset, and is published as supplied by the author(s). The author(s) retain(s) responsibility for its accuracy.






LinkedIn